深圳市亦诺微医药科技有限公司 Immvira Co. Ltd
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
ImmVira's breakthrough intravenous oncolytic virus product MVR-T3011 IV completed first dosing in Phase I clinical trial in China 2022-03-02 09:07
ImmVira's New-Generation Vector Poised to Enable CAR-T Treatment for Solid Tumors 2022-01-25 08:30
ImmVira's MVR-T3011 IV completed first 2 cohorts dose-escalation of U.S. Phase I clinical study with favorable safety data 2022-01-19 08:30
ImmVira's MVR-T3011 IV Completed First Dosing for Intravenous Administration in a U.S. Phase I Clinical Trial 2021-08-11 10:45
ImmVira's MVR-T3011 Obtained NMPA's Approval for Intravenous Administration (IV) Phase I Clinical Trial 2021-08-06 19:50
ImmVira Launches Pilot-scale Production Line to Expedite the Advancement of Next-generation OV Clinical Trials 2021-07-19 08:30
ImmVira completed the first dosing for Phase II of MVR-T3011 (intratumoral injection) in the U.S. and China 2021-06-12 11:16
ImmVira will present the U.S. Clinical Phase I Study Results of MVR-T3011 via Intratumoral Administration at ASCO 2021 2021-06-02 16:14
ImmVira Announces Preclinical and Clinical Data to Be Presented at the 2021 ASCO and AACR Annual Meeting 2021-04-08 20:47
ImmVira Announces Series C Financing with Leading Specialist Investors 2020-12-31 19:29
ImmVira and Shanghai Pharma Announce Clinical Collaboration and License Agreement for Commercialization of Novel Intratumoral Oncolytic Virus Immunotherapies 2020-08-06 23:49
Immvira Announces the Appointment of Carl Yeung as Chief Financial Officer 2020-07-01 08:30
1 2